A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ABBOTT LABORATORIES
ABT
$180.1B
Mkt Cap
$103.06
+2.29%
ABBOTT LABORATORIES (ABT) has a current P/E ratio of 27.7, compared to its historical median P/E of 33.4. The stock is currently considered Fair based on its historical valuation range.
ABBOTT LABORATORIES (ABT) has a 5-year average return on invested capital (ROIC) of 13.9%. This indicates solid capital allocation.
ABBOTT LABORATORIES (ABT) has a market capitalization of $179.5B. It is classified as a large-cap stock.
Yes, ABBOTT LABORATORIES (ABT) pays a dividend with a trailing twelve-month yield of 2.33%. The company also returns capital through share buybacks, with a buyback yield of 0.44%.
Based on historical P/E analysis, ABBOTT LABORATORIES (ABT) appears fair. The current P/E of 27.7 is 17% below its historical median of 33.4. The estimated fair value CAGR (P/E method) is 17.6%.
ABBOTT LABORATORIES (ABT) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ABBOTT LABORATORIES (ABT) reported annual revenue of $44.3 billion in its most recent fiscal year, based on SEC EDGAR filings.
Abbott Laboratories is a diversified healthcare company with four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment manufactures and sells branded generic pharmaceuticals in emerging markets outside the United States, covering therapeutic areas including gastroenterology, women's health, cardiovascular and metabolic disorders, pain and central nervous system conditions, respiratory drugs and vaccines, and biologic products including biosimilars, distributed through wholesalers, distributors, government agencies, healthcare facilities, and pharmacies. The Diagnostic Products segment offers a broad line of diagnostic systems and tests worldwide, including core laboratory and transfusion medicine systems (Alinity, ARCHITECT, Cell-Dyn), molecular diagnostics instruments (Alinity m, m2000), point-of-care systems (i-STAT), rapid diagnostics lateral flow testing (BinaxNOW, Panbio, ID NOW), and informatics and automation solutions, sold directly to blood banks, hospitals, commercial laboratories, clinics, and government agencies. The Nutritional Products segment manufactures and markets pediatric and adult nutritional products including infant formula (Similac family), adult nutritional products (Ensure, Glucerna, PediaSure), and enteral feeding products, distributed through direct channels, wholesalers, retailers, and healthcare facilities. The Medical Devices segment produces rhythm management devices (pacemakers, ICDs, cardiac monitors), electrophysiology products (ablation catheters, mapping systems), heart failure devices (HeartMate, CardioMEMS), vascular products (drug-eluting stents, vessel closure devices), structural heart devices (MitraClip, TriClip, transcatheter valves), continuous glucose monitoring systems (FreeStyle Libre, Lingo), and neuromodulation devices (spinal cord stimulators, deep brain stimulation systems), marketed and sold worldwide through direct channels, wholesalers, hospitals, and distributors. Abbott competes on technological innovation, price, product performance, convenience, service, and cost-effectiveness across all segments, with distribution models varying by geography and customer type.
【Strategic expansion and innovation acceleration】 Management expects 2026 to be powered by innovation and operational excellence, with accelerating growth in the second half of the year driven by new product launches across nutrition, electrophysiology, and core laboratory diagnostics, supported by best-in-class portfolios and improving market conditions. The company anticipates continued margin expansion of 50–70 basis points annually through gross margin improvement and operating leverage, while maintaining investments in high-growth segments including diabetes care, structural heart, and electrophysiology. Abbott is positioned to benefit from upcoming catalysts including proposed coverage expansion for continuous glucose monitoring that could add approximately 10 million newly eligible patients, approval of a dual analyte glucose monitoring system in the second half of 2026, and expected approvals of new electrophysiology products including pulsed field ablation catheters. The company remains focused on executing its growth strategy in nutrition through new product launches and pricing actions, while managing near-term headwinds in diagnostics in China and moderating respiratory testing demand, with confidence in achieving high single-digit organic sales growth and double-digit earnings per share growth.
| Metric | Target | Period |
|---|---|---|
| Organic sales growth | 6.5%-7.5% | FY2026 |
| Adjusted earnings per share | $5.55-$5.80 | FY2026 |
| Comparable sales growth | 6.5%-7.5% | FY2026 |
| Adjusted earnings per share | $5.48 | FY2026 |
| Exact Sciences incremental sales contribution | approximately $3 billion | FY2026 |
Organic sales growth (FY2026): “For the year, we forecast organic sales growth to be in the range of 6.5%-7.5%.”
Adjusted earnings per share (FY2026): “today we issued guidance for full-year adjusted earnings per share of $5.55-$5.80, which reflects 10% growth at the midpoint of the range”
Comparable sales growth (FY2026): “our full year 2026 sales growth outlook of 6.5%-7.5% is now on a comparable basis as well”
Adjusted earnings per share (FY2026): “our new guidance range midpoint of $5.48 reflects $0.20 of dilution related to the Exact Sciences acquisition”
Exact Sciences incremental sales contribution (FY2026): “we forecast the addition of Exact Sciences to add approximately $3 billion of incremental sales in 2026”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 45.1B | 44.3B | 42.0B | 40.1B | 43.7B | 43.1B |
| Net Income | 6.3B | 6.5B | 13.4B | 5.7B | 6.9B | 7.0B |
| EPS | $3.49 | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
| Free Cash Flow | 7.4B | 7.4B | 6.4B | 5.1B | 7.8B | 8.6B |
| ROIC | 7.5% | 11.3% | 13.7% | 12.3% | 15.8% | 16.3% |
| Gross Margin | - | 56.4% | 55.4% | 55.2% | 56.1% | 57.0% |
| Debt/Equity | 0.65 | 0.25 | 0.29 | 0.41 | 0.49 | 0.54 |
| Dividends/Share | $2.40 | $2.40 | $2.24 | $2.08 | $1.92 | $1.79 |
| Operating Income | 7.7B | 8.1B | 6.8B | 6.5B | 8.4B | 8.4B |
| Operating Margin | 17.1% | 18.2% | 16.3% | 16.2% | 19.2% | 19.6% |
| ROE | 12.1% | 13.0% | 31.1% | 15.1% | 19.1% | 20.5% |
| Shares Outstanding | 1,742M | 1,747M | 1,754M | 1,748M | 1,766M | 1,787M |
ABBOTT LABORATORIES passes 8 of 9 quality checks, indicating strong fundamentals.
ABBOTT LABORATORIES trades at 27.7x trailing earnings, compared to its 15-year median P/E of 33.4x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 24.2x vs a median of 28.1x. The company's 5-year average ROIC is 13.9% with a gross margin of 56.0%. Total shareholder yield (dividends + buybacks) is 2.8%. At current prices, the estimated annualized return to fair value is +3.8%.
ABBOTT LABORATORIES (ABT) has a net profit margin of 14.7%. This is a healthy margin.
ABBOTT LABORATORIES (ABT) generated $7.4 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ABBOTT LABORATORIES (ABT) has a debt-to-equity ratio of 0.25. This indicates a conservatively financed balance sheet.
ABBOTT LABORATORIES (ABT) reported earnings per share (EPS) of $3.72 in its most recent fiscal year.
ABBOTT LABORATORIES (ABT) has a return on equity (ROE) of 13.0%. This indicates moderate shareholder returns.
ABBOTT LABORATORIES (ABT) has a 5-year average gross margin of 56.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 19 years of financial data for ABBOTT LABORATORIES (ABT), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ABBOTT LABORATORIES (ABT) has a book value per share of $29.83, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects 2026 to be powered by innovation and operational excellence, with accelerating growth in the second half of the year driven by new product launches across nutrition, electrophysiology, and core laboratory diagnostics, supported by best-in-class portfolios and improving market conditions. The company anticipates continued margin expansion of 50–70 basis points annually through gross margin improvement and operating leverage, while maintaining investments in high-growth segments including diabetes care, structural heart, and electrophysiology. Abbott is positioned to benefit from upcoming catalysts including proposed coverage expansion for continuous glucose monitoring that could add approximately 10 million newly eligible patients, approval of a dual analyte glucose monitoring system in the second half of 2026, and expected approvals of new electrophysiology products including pulsed field ablation catheters. The company remains focused on executing its growth strategy in nutrition through new product launches and pricing actions, while managing near-term headwinds in diagnostics in China and moderating respiratory testing demand, with confidence in achieving high single-digit organic sales growth and double-digit earnings per share growth.
Based on recent SEC filings and earnings calls, ABBOTT LABORATORIES (ABT) has provided the following forward guidance: Organic sales growth: 6.5%-7.5% (FY2026); Adjusted earnings per share: $5.55-$5.80 (FY2026); Comparable sales growth: 6.5%-7.5% (FY2026); Adjusted earnings per share: $5.48 (FY2026); Exact Sciences incremental sales contribution: approximately $3 billion (FY2026).